Chemoresistance is the major obstacle in multiple myeloma (MM) management. We previously showed that macrophages protect myeloma cells, on a cell contact basis, from melphalan or dexamethasone-induced apoptosis in vitro. In this study, we found that macrophage-mediated myeloma drug resistance was also seen with purified macrophages from myeloma patients' bone marrow (BM) in vitro and was confirmed in vivo using the human myeloma-SCID (severe combined immunodeficient) mouse model. By profiling differentially regulated and paired plasma membrane protein genes, we showed that PSGL-1 (P-selectin glycoprotein ligand-1)/selectins and ICAM-1/CD18 played an important role in macrophage-mediated myeloma cell drug resistance, as blocking antibodies against these molecules or genetic knockdown of PSGL-1 or ICAM-1 in myeloma cells repressed macrophages' ability to protect myeloma cells. Interaction of macrophages and myeloma cells via these molecules activated Src and Erk1/2 kinases and c-myc pathways and suppressed caspase activation induced by chemotherapy drugs. Thus, our study sheds new light on the mechanism of drug resistance in MM and provides novel targets for improving the efficacy of chemotherapy in patients.
INTRODUCTION
Multiple myeloma (MM), a terminally differentiated plasma cell malignancy in the bone marrow (BM), is still an incurable disease, and chemotherapy is currently one of the most effective treatments for MM. 1, 2 However, despite the introduction of novel chemotherapy agents and advances of treatment plan, chemoresistance, especially multidrug resistance, remains the major problem in MM management. Drug resistance has been reported for all clinically used MM chemotherapy agents, including conventional chemotherapeutics melphalan, dexamethasone and doxorubicin, 3 and novel chemotherapeutics thalidomide, lenalidomide and bortezomib. 4, 5 Indeed, almost all MM patients have relapsed or refractory tumor after prior treatments. 6 Relapsed tumors are usually more resistant to drugs, especially conventional chemotherapy agents, and patients' median survival after relapse is only about 9 months. 7 Myeloma BM plays an essential role in MM drug resistance. 8, 9 For MM patients, the BM is not only where MM cells accumulate, but it also provides a homing microenvironment, which is important for the tumor development, growth, proliferation, metastasis and chemoresistance. As evidence, primary MM cells isolated from the BM microenvironment exhibit decreased viability ex vivo and increased sensitivity toward cytotoxic agents. 10 MM-BM microenvironment is constituted of both cellular and non-cellular components. Direct contact between MM cells to those BM components, and soluble factors secreted by MM-BM cells, both confer MM cell drug resistance. As expected, multiple factors are involved in MM drug resistance within the BM microenvironment, but many details of MM drug resistance are still missing.
Our previous work has shown that MM-BM has increased macrophage (MF) infiltration, compared with non-malignant BM. 10 In vitro experiments showed that MFs mediated MM drug resistance to conventional chemotherapeutics melphalan and dexamethasone. The goals of this study were to perform mechanistic studies to further elucidate the mechanism underlying MF-mediated MM drug resistance in vitro and in vivo, to identify cell surface molecules on both MM cells and MFs that were involved in cell interaction, and to investigate signaling pathways in MM cells that confer drug resistance. Such a study may provide new insight into the mechanism of drug resistance in MM and new targets for improving the efficacy of chemotherapy in MM patients.
Santa Cruz Biotecnologies (Santa Cruz, CA, USA). Immunohistochemistry antibodies against cleaved PARP were purchased from Cell Signaling, and anti-CD68 antibody was from Dako (Carpinteria, Santa Barbara, CA, USA). Flow cytometry antibodies fluorescein isothiocyanate-CD3, CD14, CD16, CD19, CD20, Annexin V and control IgG were purchased from eBioscience (San Diego, CA, USA) and ACP-CD68 and CD11c were from Biolegend.
MM cells, MFs and cell (co)cultures
Human MM cell lines ARP-1, ARK, MM.1S, CAG and U266 were maintained in RPMI-1640 medium with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C and 5% CO 2 . Primary MM cells were isolated from BM aspirates of newly diagnosed patients' by CD138 þ cell sorting.
Human MFs were generated from peripheral blood monocytes of healthy donors or myeloma patients' as described previously. 10 In brief, 20-25 millions of mononuclear cells from the blood of healthy donors were incubated in 24-well or 6-well plates for 2 h at 37 1C to remove nonadherent cells. The adherent monocytes were incubated for 7 days in medium with macrophage colony-stimulating factor (10 ng/ml) to become MF. Primary MM patients' BM-MFs were isolated from BM aspirates of myeloma patients' by CD14 þ /CD163 þ double-positive cell sorting. The sorted cells were cultured in RPMI-1640 complete medium overnight before the experiment.
For MF/MM cell coculture with direct contact, MM cells were added directly to MFs and cocultured for the indicated length of time (usually 24 h). For MF/MM cell coculture without direct contact, MM cells were cultured in transwell inserts (0.4-mm pore size, Corning Inc., Corning, NY, USA). In some experiments, MM cells in transwells were cocultured with MM cells and MFs at bottom of wells to evaluate contact-dependent soluble factors in MM drug resistance. After direct coculture, suspension MM cells were harvested and depleted of contaminating MFs by magnetic CD14 þ cell depletion (Miltenyi Biotec, Bergisch Glabach, Germany) before apoptosis assay, western blotting or microarray analysis. After MF depletion, the purity of MM cells is 499%. All studies involving primary cells were approved by the Institutional Review Board at the University of Texas, MD Anderson Cancer Center.
Apoptosis assay and flow cytometry analysis MM cell apoptosis was measured by Annexin V-binding assay as previously described. 10 In some experiments when CFSE-labeled or green fluorescent protein-expressing MM cells were used for apoptosis assay, APC-Annexin V (eBioscience) was used for apoptotic cell detection.
Expression of P-selectin, E-selectin, CD18, PSGL-1 and ICAM-1 was determined by direct immunofluorescence using fluorescein isothiocyanate -or R-phycoerythrin (PE)-conjugated antibodies. After staining, cells were resuspended in phosphate-buffered saline and analyzed by a FACScan flow cytometer (Becton Dickinson, (BD) Company, Franklin Lakes, NJ, USA). Flow cytometry analysis of myeloid dendritic cells (mDCs), plasmacytoid DCs (pDCs) and MFs was performed as described previously. 11, 12 Short hairpin RNA (shRNA) for target protein knocking down PSGL-1 was knocked down in MM cells by shRNA lentiviral infection. PSGL-1 shRNA (target sequence: 5 0 -GAGGAGTACTGAAGAGTGA-3 0 ) lentivirus was constructed as previously described. 13 After lentiviral infection, transduced cells were sorted for green fluorescent protein-expression. Similarly, ICAM-1 shRNA (target sequence 1: 5 0 -GAACAGAGTGGAAGACATA-3 0 ; and target sequence 2: 5 0 -GGTTACAGGTTCAGAGATT-3 0 ) lentivirus was constructed and used for ICAM-1 silencing in MM cells.
Microarray analysis for differentially regulated and paired membrane protein gene identification ARP-1 cells and MFs were cultured alone or cocultured with direct contact for 24 h. Total RNA was extracted from each type of the cells using TRIzol (Invitrogen). Gene expression profiles were determined by Illumina GeneArray (Illumina, Inc., San Diego, CA, USA). Three biological repeats were included in the microarray analysis.
To identify functional, paired membrane protein genes on MM cells and MFs, we hypothesized that if a pair of surface protein genes were upregulated under coculture condition, it was likely that this pair of genes were involved in MF-mediated drug resistance. Therefore, we first identified differentially upregulated genes in MM and MF using the function value (gene, i) ¼ S(log 2 (data (coculture) gene, i) À log 2 (data (alone) gene, i)). Next we ranked the genes with descending order of values, and genes with largest values ranked at the top of the list. The position of a gene in the ranked list is the score of that gene, for example. the top gene score is 1, the second gene score is 2, and so on. We then compared the ranked gene list with the human surfaceome database, 14 and produced a ranked surface-gene list. Next, we extracted each surface protein's surface interactors using the protein-protein interaction database (www.hprd.org). Finally, we ranked paired surface genes by the sum of each gene's scores. For example, gene A on MM had score 1, and its interactor gene B on MFs had score 4, and the sum of scores was 5. The gene pair with the least sum score number ranked at the top of the final list. After removing selfinteractions, a total of 1434 pairs of surface gene interactions was ranked and the top 250 genes were used for future analysis.
Immunohistochemistry analyses
Formalin-fixed, paraffin-embedded sections of tumors from tumor-bearing SCID (severe combined immunodeficient) mice were used for immunohistochemistry analyses to detect CD68-expressing MFs or cleaved PARP (apoptotic tumor cells) as described previously. 15 
MF-mediated MM chemoresistance in vivo
Six-to eight-week-old female SCID mice were housed and monitored in the MD Anderson Cancer Center animal research facility. All experiments had been approved by the Institutional Animal Care and Use Committee at the University of Texas, MD Anderson Cancer Center. Mice were subcutaneously inoculated in the right flank with one million ARP-1 and two million monocytes suspended in 100 ml phosphate-bufferd saline. For some experiments, monocytes were labeled with CFSE (Invitrogen) before inoculation. In control mice, ARP-1 cells only (1 million) were subcutaneously inoculated.
After palpable tumor developed (tumor diameter X5 mm), the presence and number of MFs in the tumors were determined. Specifically, tumors developed after ARP-1/monocytes or ARP-1 inoculations were harvested for immunohistochemistry staining for human CD68 or flow cytometry analysis for CFSE þ MFs. Some mice were treated with intraperitoneal injections of melphalan (100 mg per mouse every 3 days) for 15 days. Injections of DMSO served as a control. Five mice were included in each treatment group. In some experiment, mice were intraperitoneally injected with PSGL-1-neutralizing antibody or control IgG (100 mg per mouse, every 3 days), and treated with melphalan as described above. Tumor sizes were measured daily and blood samples were collected every 5 days. Tumor burdens were evaluated by measuring tumor size and detecting circulating human kappa chain by ELISA (Bethyl Laboratories Inc., Montgomery, AL, USA).
Statistical analysis
All data are shown as mean ± s.d. The Student t-test was used to compare various experimental groups. A P value o0.05 was considered significant.
RESULTS

MF-mediated MM drug resistance is cell contact-dependent
To test MF-mediated MM drug resistance, MM cells ARP-1, ARK or CAG, cocultured with monocyte-derived MFs from blood donors, were treated with or without the apoptotic agent, melphalan. As shown in Figure 1a , direct cell contact between MM cells and MFs, but not separated by transwell inserts, conferred MM cell drug resistance (Po0.01, compared with melphalan-treated MM cell culture alone). Interestingly, drug resistance could also be partially induced in MM cells placed on transwell inserts in the coculture of MM cells and MFs together in the bottoms, indicating that bystander MM cells could also be protected by soluble factors derived from MM/MF interaction (Figure 1a ; Po0.01, compared with melphalan-treated MM cell culture alone or MM/MF coculture). Next, we showed that MFs protected MM cells ARP-1, ARK or CAG with a wide range of MF/MM ratios (Figure 1b ; Po0.01, compared with melphalan-treated MM cell culture alone), and at different doses of melphalan treatment ( Figure 1c ). In addition, we showed that only MFs, but not monocytes, protected MM cells from melphalan-induced cell apoptosis (Figure 1d ). We extended our experiment to other cytotoxic agents such as doxorubicin and bortezomib. Our results showed that, under the coculture condition, MFs protected all tested MM cells from the chemotherapeutics-induced apoptosis (Figures 1e and f) . We do not believe that fewer apoptotic cells were detected in the cocultures because MFs engulfed apoptotic myeloma cells as our previous studies showed that similar percentages of apoptotic myeloma cells were detected in cocultures with MFs treated with or without cytochalasin D, which inhibited the endocytosis ability of MFs. 10 Overall, our findings suggested that MFs conferred MM multidrug resistance on a cell contact-dependent basis.
MFs may be important cells in an MM-BM microenvironment Others have shown that various types of BM cells, such as mDCs, pDCs and osteoclasts, promote MM cell proliferation and/or drug resistance. 10, [16] [17] [18] To investigate their clinical significance, the numbers of pDCs, mDCs and MFs in the BM of MM patients' were examined. As shown in Figure 2a (a representative result from a patients') and Figure 2b (summarized data of 10MM patients's), the percentages of BM-infiltrating MFs were significantly higher than those of mDCs or pDCs, suggesting that MFs, as abundant in the BM, may be important in protecting MM cells against chemotherapy in vivo.
Next, we used monocyte-derived MFs from MM patients' and examined their capacity to confer drug resistance. As shown in Figure 2c , patients'-derived MFs efficiently protected MM (ARP-1) cells from melphalan-induced apoptosis in a direct coculture (Po0.01, compared with melphalan-treated ARP-1 culture alone). We also isolated CD14 þ monocytes/MFs from MM patients' BM aspirates. These cells were cultured overnight first and then used for protection assay as described above. The results showed that MFs from tumor bed were also efficient at protecting MM (ARP-1) cells from melphalan-induced MM cell apoptosis (Figure 2d ; Po0.01, compared with melphalan-treated ARP-1 culture alone). Overall, our results showed that monocyte-derived MFs from blood donors and MM patients' as well as MFs isolated from the BM of MM patients' could render MM drug resistance in vitro.
Identification of upregulated, paired membrane proteins on MM cells and MFs As MF-mediated MM drug resistance is cell-contact dependent, we hypothesized that cell surface molecules on those cells were important. Specifically, cell contact happens and is stabilized via interactions between paired plasma membrane proteins on each type of cells, and the interaction might initiate downstream survival signaling transduction in MM cells. Therefore, we analyzed Figure 3a) , whereas all MFs expressed both P-selectin and E-selectin. The expression of P/Eselectins by monocyte-derived MFs was also confirmed by reverse transcriptase-PCR (Supplementary Figure 2A) .
Next, we interrupted selectins/PSGL-1 interaction using P/Eselectin-or PSGL-1-blocking antibodies, and examined MFmediated protection. As shown in Figures 3b and c , the antibodies had little effect on melphalan-induced MM (ARP-1, ARK, CAG or primary MM) cell apoptosis in cultures without MFs. However, both of the antibodies, but not control IgG, repressed MFmediated MM drug resistance and restored, at least partially, MM cell sensitivity to melphalan in direct coculture with MFs (Po0.05, compared with control IgG). We also tested MF-mediated MM chemoresistance in PSGL-1-knocked down MM cells, ARP-1 or ARK (Supplementary Figures 2B and C) . Compared with controls, the mean fluorescent intensity of surface PSGL-1 expression was decreased by 450% on knocked-down cells, suggesting a significant surface protein knockdown. By knocking down PSGL-1 in MM cells, MFs were no longer able to protect them from chemotherapy drug-induced apoptosis (Figure 3d ; Po0.01, compared with control shRNA-knocked down MM cells). Alternatively, we showed that E-selectin-FC fusion protein, which binds with PSGL-1 on MM cells and is agonistic, could also protect, to a certain degree, MM cells ARP-1, ARK or CAG from melphalaninduced apoptosis (Figure 3e ; Po0.01, compared with melphalantreated MM cells).
Finally, as monocytes did not protect MM cells from melphalaninduced cell death, we measured the expression of selectins during MF differentiation. As shown in Figure 3f , MFs had increased E-selectin expression as compared with monocytes (Po0.05). Overall, our findings suggested that MF expressed P/E-selectins, and MM cells expressed their ligand PSGL-1. Direct cell contact between MF and MM cells enabled PSGL-1/selectins interaction, which is crucial for MF-mediated drug resistance in MM cells.
ICAM-1/CD18 are critical adhesion molecules for MF-mediated drug resistance Second, we examined the role of ICAM-1/CD18 in MM drug resistance on the basis of our previous study. 10 All tested MM cell lines and primary MM cells expressed ICAM-1, and monocytederived MFs and purified MFs from MM patients' BM expressed CD18 (Figure 4a ). Functional tests showed that ICAM-1 or CD18-blocking antibodies attenuated MF-mediated MM (CAG, ARK, U266 or primary MM) cell drug resistance (Figures 4b and c Figures 3A and B) were not protected by MFs against melphalan-induced apoptosis ( Figure 4d ). Thus, our findings suggested that cell membrane proteins CD18 (on MFs) and ICAM-1 (on MM cells) also played an important role in MF-mediated MM drug resistance.
MF-mediated MM drug resistance is associated with survival signaling in MM cells
We hypothesized that MF/MM cocultures activated cell survival signaling in MM cells, which conferred MM multidrug resistance. First, we examined MM cell apoptosis signaling under (co)culture conditions. As shown in Figure 5a , melphalan treatment stimulated PARP and caspase-3 cleavage, both of which are characteristics of apoptotic cells. However, in MM (ARP-1) cells cocultured with MFs, melphalan-induced PARP and caspase-3 cleavages were highly repressed. Next, we studied the signaling molecules in MM cells. We found that proto-oncoprotein c-myc and phosphorylated Src and Erk1/2 kinases were upregulated in MF-cocultured ARP-1 cells, but not in ARP-1 cells cultured alone or cocultured in transwell inserts (Figure 5b ). Similar findings were also observed from other MM cell lines (Supplementary Figure 4A) .
Next we studied the downstream signaling of PSGL-1 using PSGL-1-knocked down ARP-1 cells. As shown in Figure 5c , coculture with MFs did not stimulate Erk1/2 phosphorylation or c-myc overexpression in PSGL-1-knocked down ARP-1 cells. Similar findings were also observed in PSGL-1-knocked down ARK cells (Supplementary Figures 4B and C) . Such findings suggested that PSGL-1-mediated MM drug resistance may be through Erk1/2 pathway activation and c-myc upregulation. In line with this finding, activation of PSGL-1 by soluble E-selectin-Fc fusion protein also induced phosphorylation of Erk1/2 (Figure 5d ). Conversely, MF-mediated MM drug resistance was highly repressed by inhibitors to Erk, Src or c-myc (Figures 5e-g ; Po0.01, compared with control).
Our results that PSGL-1 expression in ARP-1 was upregulated after coculture (Figure 5b ) suggested a feedback loop of PSGL-1 in MF-mediated MM drug resistance. As transwell-cocultured ARP-1 also had increased PSGL-1, it was likely that some soluble factors contributed to PSGL-1 upregulation. Further test showed that PSGL-1 overexpression was regulated by IFN-a. IFN-a-blocking antibody repressed MF coculture-induced PSGL-1 overexpression (Supplementary Figure 4D) . However, IFN-a-blocking antibody did not affect MF-mediated MM drug resistance (Supplementary Figure 4E) .
In vivo effects of MF-mediated MM drug resistance
The human MM-SCID mouse model 15 was used to examine whether MFs could protect MM cells from drug-induced apoptosis in vivo. Human myeloma cells and (CFSE-labeled, in some experiments) monocytes were mixed and injected into SCID mice as detailed in Materials and Methods. After tumors were developed, CFSE-labeled human MFs in tumors could be observed and enumerated by immunohistochemistry staining using anti-human CD68 antibody or flow cytometry analyses for CFSE-labeled cells (Figure 6a ). To measure melphalan-induced cell death in vivo, mice bearing ARP-1 tumor with human MFs or ARP-1 tumor alone were treated with the drug daily for three consecutive days. After the treatment, tumors were harvested and subjected for immunohistochemistry analysis with anti-cPARP antibody (Figure 6b ; left panel) and apoptosis assay (Figure 6b ; right panel). Our results showed that melphalan-induced tumorcell apoptosis was significantly repressed when human MFs were present, suggesting that MFs protected MM cells from melphalaninduced apoptosis in vivo. Consistently, co-injection of human MFs resulted in significantly compromised therapeutic effects of melphalan (a 15-day treatment schedule) on the tumors, measured as tumor volume (Figure 6c ; Po0.05, compared with melphalan treatment) or circulating human kappa chain (Figure 6d ; Po0.01, compared with melphalan treatment). To confirm that selectin/PSGL-1 pathway was involved in vivo, mice bearing ARP-1/MF tumors were treated with PSGL-1-neutralizing antibody together with melphalan as described above. The result showed that PSGL-1-neutralizing antibody significantly repressed MF-mediated drug resistance in vivo (Figure 6e ; Po0.01, compared with IgG treatment).
Interestingly, we also found that co-injection of MFs led to a faster tumor development as compared with injection of MM (ARP-1) cell alone (Supplementary Figure 5A ; Po0.01). Although palpable tumors in each group grew at a similar rate (Figure 6c) , MF-ARP-1 tumors developed earlier than ARP-1-alone tumors did (Supplementary Figure 5A) . We investigated whether MFs could affect MM proliferation, and showed that MF coculture promoted slightly but significantly myeloma cell proliferation (Supplementary Figure 5B ; Po0.05 to Po0.01, compared with ARP-1 cell alone). Moreover, using colony-formation assay, we showed that MF coculture significantly promoted MM cell colony formation on soft agar (Supplementary Figure 5C ; Po0.01, compared with ARP-1 cells alone), indicating that MF may enhance MM proliferation and tumorigenicity in vivo.
DISCUSSION
It has been well documented that MFs infiltrate into the tumor bed of various solid tumors and those MFs are termed tumor-associated MFs tumor-associated MFs. 19 Tumor-associated MFs exhibit tumor promoting activities by increasing tumor angiogenesis, metastasis and suppressing anti-tumor immunity. 20, 21 In this study, we demonstrated a novel function, that is, promoting multidrug resistance in MM, for these cells.
MF-mediated MM multidrug resistance required direct cell contact between MFs and MM cells. MFs conferred strong drug resistance to MM cells, which might be mediated by paired cell surface protein interactions. In this study, we demonstrated that two of those paired membrane proteins, selectins/PSGL-1 and CD18/ICAM-1, were important for MF/MM cell interaction to confer drug resistance to MM cells. Selecins/PSGL-1 proteins have been well characterized in leukocyte migration. 22 Selectin expression on mouse MFs has been reported. 23, 24 Both P-selectins and E-selectins have a common ligand, PSGL-1. One recent publication showed that MM cells had increasing PSGL-1 expression during disease progression, and PSGL-1 was important for MM homing to the BM and MM drug resistance. 25 In our studies, we found that PSGL-1 expression had limited effect on MM spontaneous apoptosis, but was critical for MF-mediated MM drug resistance. The other identified paired membrane proteins are CD18/ICAM-1. Previous studies have shown that MM cells with high ICAM-1 expression have increased cell survival. 26 As an adhesion molecule, ICAM-1 interacts with CD18 on the counterpart cells. Specifically, CD18 may associate with CD11a, CD11b or CD11c and form complexes known as LFA-1, Mac-1 or p150/95, respectively. 27 However, none of the blocking antibodies to these molecules (CD11a, CD11b, and CD11c) were able to affect MF-mediated MM drug resistance. This may indicate that CD11 molecules had no direct interaction with ICAM-1 or MM cells. However, it is likely that more membrane proteins are involved and we are actively working to identify them.
Although our data clearly showed that cell-cell contact was required for MF-mediated protection of MM drug resistance, a role for soluble factors in MF-mediated MM drug resistance cannot be ruled out. As shown in Figure 1a , culture of MFs and MM cells separately by transwell inserts failed to protect MM cells, but MF-MM cell direct coculture resulted in a protection of bystander MM cells in the transwell inserts. These observations indicated that direct coculture of MFs and MM cells led to release of soluble factors that protected the by-stander MM cells. Our previous study showed that IL-6 was upregulated in the coculture but IL-6-neutralizing antibody did not compromise the protective effect. 10 Therefore, further studies are required to define the protective soluble factors.
Our data also showed that MFs mediated the multidrug resistance of MM cells to both conventional chemotherapy drugs and novel agents such as bortezomib. As those drugs have different tumoricidal mechanisms, our results suggested that MFmediated drug resistance may be associated with activation of canonical survival signaling pathways in MM cells. 28, 29 Indeed, we observed Src and Erk1/2 kinase activation and c-myc accumulation in MM cells following coculture with MFs, all of which have been shown to promote MM cell survival and drug resistance. 30, 31 We also identified that Erk kinase activation and c-myc overexpression were downstream of PSGL-1 engagement. The contact-dependent intra-MM survival signaling activation may indicate an epigenetic alteration of MM after MF infiltration. On the basis of our findings, it is highly possible that MF infiltration in tumor bed renders MM cells, especially MM cells directly interacting with surrounding MFs, with pro-survival and drug resistance capacity. Furthermore, soluble factors derived from the interaction of MM cells and MFs also support bystander MM cells to develop drug resistance. Thus, it is plausible that these MF-interacting and surrounding MM cells are better protected against chemotherapy and become relapsed/refractory tumors after chemotherapy. Further studies are warranted to investigate MF infiltration of BM and MM prognosis to further evaluate and confirm the clinical relevance of MFs in the disease progression. 
